Skip to main content

Advertisement

SpringerLink
Log in

The ADP Antagonist MRS2179 Regulates the Phenotype of Smooth Muscle Cells to Limit Intimal Hyperplasia

  • ORIGINAL ARTICLE
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Abstract

Purpose

ADP plays an important part in platelet aggregation by activating P2Y1 and P2Y12 receptors. The ADP antagonist MRS2179 has been used in thrombosis-related treatments but its effects on vein graft (VG) remodeling is undefined. We examined the effect of MRS2179 on VG intimal hyperplasia and explored the mechanism of action.

Methods

A mouse model of VG transplantation was established. Mice underwent surgery and received MRS2179 by intraperitoneal injection every other day for 3 weeks. VG remodeling was assessed 4-weeks later. Vascular smooth muscle cells (VSMCs) were isolated and treated with MRS2179. The effect of MRS2179 on the proliferation, migration and inflammatory-cytokine expression of VSMCs was also evaluated.

Results

MRS2179 significantly inhibited VSMC proliferation compared with the control group. Significant inhibitory effects of MRS2179 on VSMC migration was observed in two-dimensional and three-dimensional models. The extent of intimal hyperplasia was significantly less in MRS2179 treated mice than in controls. Reduced migration of macrophage was found in MRS2179 treated mice. Expression of the inflammatory cytokines IL-1β and TNF-α was decreased significantly in the MRS2179 treated group. In addition, decreased phosphorylation was found on Akt, Erk1/2 and p38.

Conclusions

These data demonstrate that MRS2179 inhibits neointima formation in VGs by regulating the proliferation, and migration of VSMCs, macrophage migration, inflammatory-cytokine secretion and related signaling pathway. Our study provides novel insights regarding purinergic signaling in SMCs in vivo. The P2Y1 receptor may serve as a therapeutic target in neointima formation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Motwani JG, Topol EJ. Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. Circulation. 1998;97(9):916–31.

    Article  CAS  PubMed  Google Scholar 

  2. Dale N. A classic review on extracellular ATP and its signalling functions that helped to define the field’s agenda for many years. Biochem J. 2012;2012(1):1–6. doi: 10.1042/BJ20121145

  3. Wihlborg AK, Wang L, Braun OO, Eyjolfsson A, Gustafsson R, Gudbjartsson T, et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol. 2004;24(10):1810–5.

    Article  CAS  PubMed  Google Scholar 

  4. Burnstock G. Purinergic regulation of vascular tone and remodelling. Auton Autacoid Pharmacol. 2009;29(3):63–72.

    Article  CAS  PubMed  Google Scholar 

  5. Erlinge D, Burnstock G. P2 receptors in cardiovascular regulation and disease. Purinergic Signal. 2008;4(1):1–20.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  6. Baurand A, Gachet C. The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179. Cardiovasc Drug Rev. 2003;21(1):67–76.

    Article  CAS  PubMed  Google Scholar 

  7. Ray JL, Leach R, Herbert JM, Benson M. Isolation of vascular smooth muscle cells from a single murine aorta. Methods Cell Sci. 2001;23(4):185–8.

    Article  CAS  PubMed  Google Scholar 

  8. Garg N, Goyal N, Strawn TL, Wu J, Mann KM, Lawrence DA, et al. Plasminogen activator inhibitor-1 and vitronectin expression level and stoichiometry regulate vascular smooth muscle cell migration through physiological collagen matrices. J Thromb Haemost. 2010;8(8):1847–54.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  9. Zou Y, Dietrich H, Hu Y, Metzler B, Wick G, Xu Q. Mouse model of venous bypass graft arteriosclerosis. Am J Pathol. 1998;153(4):1301–10.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  10. Ji Y, Strawn TL, Grunz EA, Stevenson MJ, Lohman AW, Lawrence DA, et al. Multifaceted role of plasminogen activator inhibitor-1 in regulating early remodeling of vein bypass grafts. Arterioscler Thromb Vasc Biol. 2011;31(8):1781–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Xing D, Gong K, Feng W, Nozell SE, Chen YF, Chatham JC, et al. O-GlcNAc modification of NFkappaB p65 inhibits TNF-alpha-induced inflammatory mediator expression in rat aortic smooth muscle cells. PLoS One. 2011;6(8):e24021.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Rauch BH, Rosenkranz AC, Ermler S, Bohm A, Driessen J, Fischer JW, et al. Regulation of functionally active P2Y12 ADP receptors by thrombin in human smooth muscle cells and the presence of P2Y12 in carotid artery lesions. Arterioscler Thromb Vasc Biol. 2010;30(12):2434–42.

    Article  CAS  PubMed  Google Scholar 

  13. Harada K, Matsumoto Y, Umemura K. Adenosine diphosphate receptor P2Y12-mediated migration of host smooth muscle-like cells and leukocytes in the development of transplant arteriosclerosis. Transplantation. 2011;92(2):148–54.

    Article  CAS  PubMed  Google Scholar 

  14. Hogberg C, Svensson H, Gustafsson R, Eyjolfsson A, Erlinge D. The reversible oral P2Y12 antagonist AZD6140 inhibits ADP-induced contractions in murine and human vasculature. Int J Cardiol. 2010;142(2):187–92.

    Article  PubMed  Google Scholar 

  15. Stark VK, Warner TF, Hoch JR. An ultrastructural study of progressive intimal hyperplasia in rat vein grafts. J Vasc Surg. 1997;26(1):94–103.

    Article  CAS  PubMed  Google Scholar 

  16. Hoch JR, Stark VK, van Rooijen N, Kim JL, Nutt MP, Warner TF. Macrophage depletion alters vein graft intimal hyperplasia. Surgery. 1999;126(2):428.

    Article  CAS  PubMed  Google Scholar 

  17. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol. 2006;6(7):508–19.

    Article  CAS  PubMed  Google Scholar 

  18. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res. 2008;79(3):360–76.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Lin YC, Chiang CH, Chang LT, Sun CK, Leu S, Shao PL, et al. Simvastatin attenuates the additive effects of TNF-alpha and IL-18 on the connexin 43 up-regulation and over-proliferation of cultured aortic smooth muscle cells. Cytokine. 2013;62(3):341–51.

    Article  CAS  PubMed  Google Scholar 

  20. Choi HC, Kim HS, Lee KY, Chang KC, Kang YJ. NS-398, a selective COX-2 inhibitor, inhibits proliferation of IL-1beta-stimulated vascular smooth muscle cells by induction of HO-1. Biochem Biophys Res Commun. 2008;376(4):753–7.

    Article  CAS  PubMed  Google Scholar 

  21. Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost. 2002;88(4):554–67.

    CAS  PubMed  Google Scholar 

  22. Baarsma HA, Meurs H, Halayko AJ, Menzen MH, Schmidt M, Kerstjens HA, et al. Glycogen synthase kinase-3 regulates cigarette smoke extract- and IL-1beta-induced cytokine secretion by airway smooth muscle. Am J Physiol Lung Cell Mol Physiol. 2011;300(6):L910–9.

    Article  CAS  PubMed  Google Scholar 

  23. Seidel P, Merfort I, Hughes JM, Oliver BG, Tamm M, Roth M. Dimethylfumarate inhibits NF-{kappa}B function at multiple levels to limit airway smooth muscle cell cytokine secretion. Am J Physiol Lung Cell Mol Physiol. 2009;297(2):L326–39.

    Article  CAS  PubMed  Google Scholar 

  24. Nair P, Radford K, Fanat A, Janssen LJ, Peters-Golden M, Cox PG. The effects of leptin on airway smooth muscle responses. Am J Respir Cell Mol Biol. 2008;39(4):475–81.

    Article  CAS  PubMed  Google Scholar 

  25. Li P, Li YL, Li ZY, Wu YN, Zhang CC, AX, et al. Cross talk between vascular smooth muscle cells and monocytes through interleukin-1beta/interleukin-18 signaling promotes vein graft thickening. Arterioscler Thromb Vasc Biol. 2014;34(9):2001–11.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported by grants from Scientific Research Funding of Shanghai Jiao Tong University Affiliated Sixth People’s Hospital (No.1343).

Conflict of Interest

The authors declare no competing interests.

Author information

Authors and Affiliations

  1. Department of Cardiology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, 600 Yishan Rd, Shanghai, 200233, China

    Rong Liu, Shixin Ma, Zhigang Lu, Hong Shen, Leiqing Sun & Meng Wei

Authors
  1. Rong Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shixin Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhigang Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hong Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leiqing Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Meng Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Meng Wei.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Liu, R., Ma, S., Lu, Z. et al. The ADP Antagonist MRS2179 Regulates the Phenotype of Smooth Muscle Cells to Limit Intimal Hyperplasia. Cardiovasc Drugs Ther 29, 23–29 (2015). https://doi.org/10.1007/s10557-014-6561-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10557-014-6561-6

Keywords

Search

Navigation